Compare Byrna Technologies Inc (BYRN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Novartis AG — how do they compare? Byrna Technologies Inc trades at $4.68 (market cap $106.74M), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 2767.2× Byrna Technologies Inc's market cap, and Novartis AG pays a 3.07% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | NVS | |
|---|---|---|
Market Cap | $106.74M | $295.37B |
Sector | Technology | Health |
52-Week High | $27.63 | $168.62 |
52-Week Low | $3.18 | $119.31 |
Enterprise Value | $98.35M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.45, up 2.06% today, but faces bearish technical signals and recent earnings challenges. The company reported a Q2 2026 loss of $0.44 per share, missing estimates, with revenue declining 42.5% year-over-year. Despite a 71.4% analyst buy rating, negative net income margin and cash flow concerns highlight operational headwinds. Recent management appointments aim to revitalize marketing and retail growth.
Outlook remains cautious due to weak sales trends and profitability issues, though strategic hires and acquisitions could support a turnaround. Key risks include sustained revenue declines and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
